Aleeto
Phase 2Small molecule
Aleeto is one of 50 small molecule programs targeting Ischemic stroke. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
119 competitors in Ischemic Stroke
#DrugCompanyPhaseTrials
1Tnkase
RochePhase 3
Atorvastatin Calcium
Merck & Co.Phase 3
Butylphthalide
PPeking Union Medical College Hospital
Phase 3
PCSK9 Inhibitor
YYun Dai Chen
Phase 3
Aggrastat
MMedicure
Phase 3
Edaravone Dexborneol
SSimcere Pharmaceutical Co., Ltd
Phase 3
Tenecteplase or Alteplase
IInsel Gruppe AG, University Hospital Bern
Phase 3
Proamatine
TakedaPreclinical
Levaquin
WWim Janssens
Preclinical
Aleeto
BBeijing Tiantan Hospital
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Amyotrophic Lateral Sclerosis1 trial
Safety and Preliminary Efficacy of Aleeto in Amyotrophic Lateral Sclerosis
Unknown status·—·Phase 1·NCT06181526·24 enrolled
Multiple System Atrophy1 trial
The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy
Recruiting·—·Phase 1·NCT06765733·20 enrolled
Ischemic stroke1 trial
Aleeto in Acute ISchemic Stroke：A RandomISed Controlled Clinical Trial
Recruiting·—·Phase 2·NCT06759753·192 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Aleeto. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- BBeijing Tiantan Hospital